Decision: Unfavourable

Decisions Table

Study Title:

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigators Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

  • NREC Code:

    22-NREC-CT-104

  • Decision:

    Unfavourable

  • Meeting Date:

    08/06/2022

  • Study Type:

    CT application

  • Principal Investigator:

    DR Paula Calvert

  • PI Institution:

    University Hospital Waterford

  • Sponsor:

    Seagen Inc.

Scroll to Top